Alemtuzumab biosimilar(BioXpress)

阿仑单抗生物类似药（BioXpress）

Report date: 2022/03/16 14:40:25

Base Information

Drug NameAlemtuzumab biosimilar(BioXpress)
Drug Alias NameBX-1523BXT-1523
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCAMPATH-1 antigen inhibitors
TargetsCAMPATH-1 antigen
Therapy Area/IndicationsMultiple SclerosisLeukemia, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerland
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaN/A
Originator CompaniesBioxpress Therapeutics Sa
China Registration ClassN/A

Develop Information

Active CompaniesBioxpress Therapeutics Sa
Inactive CompaniesN/A
Active IndicationsMultiple SclerosisLeukemia, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A